Search

Displaying results 4731 - 4740 of 10000 in total
  1. Drug

    TA-CIN

    go.drugbank.com/drugs/DB05809
    Investigational

    TA-CIN is a subunit vaccine comprising L2/E6/E7 proteins from Human Papillomavirus (HPV16), designed to generate a strong cellular immune response against HPV-infected cells.

    Synonyms: TA-CIN
  2. Drug

    TM30339

    go.drugbank.com/drugs/DB05085
    Experimental

    TM30339 thus imitates a natural mechanism, a satiety signal from the gastrointestinal system involved in the regulation of food intake in humans. TM30339 is developed for the treatment of obesity. … TM30339 is an analogue of the natural hormone Pancreatic Polypeptide (PP), which is released in connection with meals.

  3. Drug

    ACA 125

    go.drugbank.com/drugs/DB05489
    Investigational

    ACA-125 mimics the tumor-associated antigen CA-125, which can be detected in about 80% of ovarian carcinomas. … To create ACA-125, a hybridoma cell was adapted to serum-free medium and antibody was produced in a hollow fiber cell culture system. Positive clinical results are now being reported.

  4. Drug

    PRX-07034

    go.drugbank.com/drugs/DB05993
    Experimental

  5. Drug

    Cefpodoxime

    go.drugbank.com/drugs/DB01416
    ApprovedInvestigationalVet approved

    Commonly used to treat acute otitis media, pharyngitis, and sinusitis, cefpodoxime proxetil is a prodrug which is absorbed and de-esterified by the intestinal mucosa to Cefpodoxime. … Cefpodoxime is an oral third generation cephalosporin antibiotic with effectiveness against most Gram positive and Gram negative bacteria.

    Mixtures: INFEX PLUS 100/62.5 MG/5 ML ORAL SUSPANSIYON HAZIRLAMAK ICIN KURU TOZ, 100 ML, INFEX PLUS 40/62.5 MG/5 ML ORAL SUSPANSIYON HAZIRLAMAK ICIN KURU TOZ, 100 MLCategories: Heterocyclic Compounds, 2-Ring
  6. Drug

    TRX1

    go.drugbank.com/drugs/DB05863
    Experimental

    TRX1 is being developed for the potential treatment of autoimmune diseases in collaboration with Genentech, Inc. TolerRx is currently conducting a Phase I clinical study of TRX1 in the United Kingdom. … TRX1 is a humanized antibody that binds to the CD4 receptor found on a subset of T cells.

  7. Drug

    Rimiducid

    go.drugbank.com/drugs/DB04974
    Investigational

    Rimiducid is a lipid-permeable tacrolimus analogue and a protein dimerizer. … [A187496,L9521] The combination use of rimiducid with immunotherapies for enhanced therapeutic effectiveness is currently under investigation.

  8. Drug

    Dexpramipexole

    go.drugbank.com/drugs/DB15130
    Investigational

    Dexpramipexole is under investigation in clinical trial NCT01511029 (Study to Evaluate the QTC Interval in Healthy Volunteers Dosed With Dexpramipexole (QTC = Electrocardiogram (ECG) Interval Measured … From the Onset of the QRS Complex to the End of the T Wave Corrected for Heart Rate)).

    Categories: Compounds used in a research, industrial, or household setting, Heterocyclic Compounds, 1-Ring
  9. Drug

    Cintredekin besudotox

    go.drugbank.com/drugs/DB05305
    Investigational

    Cintredekin besudotox is made from a human protein, Interleukin 13 (IL13), linked to a bacterial toxin, _Pseudomonas exotoxin_ (PE). The IL13 portion binds to receptors on the tumor. … Cintredekin besudotox has been developed as a specific tumor-targeting agent, which is administered by positive-pressure convection-enhanced delivery (CED) directly to brain tissue at risk for residual

  10. Drug

    Pemivibart

    go.drugbank.com/drugs/DB18720
    Investigational

    Pemivibart (Pemgarda) is a human IgG1 monoclonal antibody targeting the SARS-CoV-2 spike protein receptor binding domain. … [L50326] It received emergency use authorization (EUA) from the FDA in March 2024 for pre-exposure prophylaxis (PrEP) of COVID-19 in certain high-risk patient populations.